MeSH tree: C15.604.515.569.480.350
Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester's Wilmot Cancer Institute. And he isn't alone: 70% of patients in the trial who had advanced-stage ...
Mar 1, 2026
0
3
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
Dec 8, 2025
0
0
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard ...
Dec 8, 2025
0
0
A new study from Karolinska Institutet, published in Cell Reports Medicine, shows that follicular lymphoma (FL), a common type of blood cancer, is not one single disease but consists of three genetically distinct subtypes. ...
Aug 15, 2025
0
16
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts, a phenomenon they describe ...
Aug 12, 2025
0
13
Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the proliferation and apoptosis of ...
Jul 9, 2025
0
0
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Jun 23, 2025
0
0
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
47
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Dec 5, 2024
0
7
CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine.
Jul 18, 2024
0
13
